Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT06076642 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06076642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06076642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 4, 2024
Completion date
May 16, 2028
Enrollment
53 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)